Retail prices for 260 widely used brand-name prescription drugs last year increased by an average 2.9%, more than twice the general rate of inflation, according to a report released yesterday by AARP’s Public Policy Institute.
 
“Increases in the retail price of brand name prescription drugs have a corresponding impact on the cost of therapy for the individual and for all other payers,” the authors note. “In 2020, the average cost of therapy for a brand name prescription drug, based on the market basket in this study, was $6,600 per year.”
 
A second AARP PPI analysis found that Medicare Part D spent nearly $40 billion more on 50 top brand-name drugs between 2015 and 2019 because drug price increases exceeded inflation.

 

Related News Articles

Headline
The Centers for Medicare & Medicaid Services yesterday released a memo and timeline outlining how it will approach implementing the Inflation…
Headline
Price increases for over 1,200 drugs exceeded inflation between July 2021 and July 2022, including many drugs used to treat cancer and other chronic conditions…
Headline
The Centers for Medicare & Medicaid Services yesterday released premium and cost-sharing information for Medicare Advantage and Part D prescription drug…
Headline
In a study reported this week in JAMA Network Open, researchers found no association between a drug’s list price and research and development costs. The study…
Headline
The Consumer Price Index has climbed 8.6% over the past 12 months before seasonal adjustment, the fastest increase in over 40 years, the Bureau of Labor…
Headline
Launch prices for new brand-name prescription drugs increased 20% per year between 2008 and 2021, according to a study reported yesterday in JAMA. Median…